WASHINGTON, Oct. 12, 2021 /PRNewswire/ — A group of leading, global life sciences and technology companies today announced a series of endorsements for pandemic preparedness legislation recently introduced by Congress. The Securing America’s Medicines and Supply (SAMS) Coalition believes the endorsements represent important policy proposals to spur innovation and provide critical drugs and medical supplies to U.S. patients.
SAMS’ endorsements coincide with recent actions taken by the Biden-Harris Administration and Congress to increase the resiliency of the supply chain within the U.S. and boost U.S. production of pharmaceutical products and personal protective equipment (PPE). These new legislative proposals encompass a variety of measures, including trade and tax reforms to encourage domestic manufacturing, the expansion of U.S. purchase agreement programs for important medical infrastructure, novel opportunities to promote U.S.-made pharmaceuticals, and measures to strengthen procurement to the strategic national stockpile (SNS).
“Congress is building on good ideas to strengthen our medical supply chain now— not in decades to come,” said David Sanders, Executive Director of SAMS and Vice President of Government Affairs and Policy at Coherus Biosciences. “Our multi-industry coalition endorses these bills because they will help to ensure that our country’s medical supply will be better positioned to help patients through this and the next public health crisis and create more U.S. jobs.”
SAMS looks forward to working with Congress as it addresses the ongoing impact of the COVID-19 pandemic as well as preparing for future global health threats.
To learn more about SAMS, please visit www.samscoalition.org.
Policies that Promote Non-Dilutive Funding Opportunities
S. 1693 | Medical Supplies for Pandemics Act of 2021
Bennet (D-CO); Tillis (R-NC)
S. 2640 | Disease X Act
S. 2589 | Securing America’s Medical Cabinet Act of 2021
Blackburn (R-TN); Menendez (D-NJ)
S. 2307 | COVID-19 and Pandemic Response Centers of Excellence Act
Gillibrand (D-NY); Boozman (R-AR); Cassidy (R-LA)
S. 2662 | Industrial Finance Corporation Act
S. 2467 | Public Health Response and Accountability Act
Cassidy (R-LA); Schatz (D-HI); Smith (D-MN)
Policies that Set Preference for U.S. Products
H.R. 3683 | Securing America’s Pharmaceutical Supply Chain
Stauber (R-MN-08); Garamendi (D-CA-03)
H.R. 4470 | Made in America Pandemic Preparedness Act
Maloney (D-NY-12); Comer (R-KY-01)
S. 2082 | MADE in America Act
Rosen (D-NV); Scott (R-SC); Carter (R-GA-01); Soto (D-FL-09)
S. 1176 | Onshoring Essential Antibiotics Act
Smith (D-MN); Cassidy (R-LA)
S. 2740 | PREPARE Act
Brown (D-OH); Cassidy (R-LA)
S. 1366 | Pharmaceutical Supply Chain Defense and Enhancement Act
Warren (D-MA); Smith (D-MN)
Policies that Promote Allied Partnerships
H.R. 2118 | Securing America from Epidemics Act
Bera (D-CA-07); Fitzpatrick (R-PA-01)
About Securing America’s Medicines and Supply
Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States—and among U.S. allies. SAMS seeks to drive implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.
SOURCE Securing America’s Medicines and Supply (SAMS)